Related Experiment Videos
Recurrent chromosomal aberrations in peripheral T-cell lymphoma.
A Montaldi1, T Chisesi, V Stracca-Pansa
1Service of Immunology, Blood Transfusion, and Human Genetics, Ospedale San Bortolo, Vicenza, Italy.
Cancer Genetics and Cytogenetics
|August 1, 1990
Summary
Chromosomal abnormalities in peripheral T-cell lymphomas (PTCL) were analyzed. Rearrangements of chromosome 14 and gains of chromosome 8 were common, aiding in PTCL classification.
Area of Science:
- Oncology
- Genetics
- Immunology
Background:
- Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of aggressive non-Hodgkin lymphomas.
- Accurate classification of PTCL is crucial for appropriate treatment and prognosis.
- Cytogenetic abnormalities play a significant role in the pathogenesis and classification of lymphoid malignancies.
Purpose of the Study:
- To investigate the cytogenetic landscape of peripheral T-cell lymphomas (PTCL).
- To identify recurrent chromosomal abnormalities in PTCL.
- To assess the utility of cytogenetic findings in the recognition and classification of PTCL.
Main Methods:
- Histological, immunological, and cytogenetic analyses were performed on neoplastic tissues from seven PTCL patients.
- Karyotyping was used to detect clonal chromosomal abnormalities.
- Specific chromosomal regions, including chromosome 14q11.2 and chromosome 8q, were examined.
Main Results:
- Clonal chromosomal abnormalities were identified in five out of seven PTCL cases.
- The most frequent aberration was rearrangement of chromosome 14 with a breakpoint at 14q11.2, observed in four patients.
- Aberrations involving chromosome 8 occurred in four patients, with three exhibiting an extra 8q.
Conclusions:
- Specific chromosomal regions may serve as common breakpoints in malignant diseases affecting similar cell types.
- Cytogenetic analysis can provide valuable insights for the recognition and classification of peripheral T-cell lymphomas.
- Recurrent chromosomal aberrations in PTCL highlight potential pathogenetic mechanisms and therapeutic targets.